Tadalafil Tablet
Product Images NDC 70518-4534

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 70518-4534). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Tadalafil 20 mg tablet bottle label showing quantity of 12 tablets. The label indicates the manufacturer as RemedyRepack Inc. and includes storage instructions. The tablets are described as oval yellow with 'T 20' imprint. The label includes NDC 70518-4534 and original manufacturer Ajanta Pharma USA Inc.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment period. The graph compares Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles). Tadalafil shows a greater decrease in score over time, with statistically significant difference noted at 12 weeks (p<0.01). The x-axis represents duration of treatment in weeks, and the y-axis represents change from baseline in IPSS Total Score.*

FDA Label Image

Figure1 (Tadalafil Figure1)

Four line graphs presenting the difference in blood pressure measurements (standing systolic, standing diastolic, supine systolic, and supine diastolic) over time in hours (0 to 96) comparing tadalafil versus placebo. The y-axes represent blood pressure difference in mmHg for each condition, with error bars shown for each data point.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs depict the effect of Tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure over 24 hours post-dose. The x-axes show time in hours; the y-axes show changes in systolic blood pressure (mmHg).*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph depicting systolic blood pressure (mmHg) changes over 12 hours following administration of tadalafil or placebo in combination with doxazosin. The x-axis represents time post-dose, and the y-axis shows systolic blood pressure changes in mmHg. Four data series compare tadalafil dosing at 8:00 and 20:00 hours versus placebo, all combined with 8 mg daily doxazosin at 8:00.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) over time (hours). It compares single 20-mg tadalafil dose, single 5-mg tadalafil dose, and once-daily 5-mg tadalafil after 5 days of administration, illustrating concentration decline patterns over a 120-hour period.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing changes from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo groups. The x-axis represents duration of treatment in weeks, and the y-axis shows change from baseline in IPSS total score, with Tadalafil showing a greater decrease over time compared to placebo, with significant difference noted (p<0.01).*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph illustrating the change from baseline in IPSS total score over a 12-week treatment period. It compares Tadalafil 5 mg (solid line with circles) and placebo (dashed line with triangles), showing greater score reduction with Tadalafil, with statistical significance marked at p<0.01.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy with Tadalafil/Finasteride versus Placebo/Finasteride. The vertical axis measures change from baseline, and the horizontal axis represents weeks of therapy at 0, 4, 12, and 26 weeks. The graph indicates a greater reduction with Tadalafil/Finasteride at each time point, with statistical significance noted at p<0.001 and p<0.05 for certain points.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure diagram of Tadalafil, illustrating its molecular configuration with rings and functional groups, corresponding to the active ingredient in the prescription drug Tadalafil.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.